Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat–C-terminal heptad repeat interactions and C-peptides’ anti-HIV activity-Reference-Cited by-同舟云学术

Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat–C-terminal heptad repeat interactions and C-peptides’ anti-HIV activity

Published:2014-06-01 Issue:9 Volume:28 Page:1251-1260
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Zheng Baohua,Wang Kun,Lu Lu,Yu Fei,Cheng Maosheng,Jiang Shibo,Liu Keliang,Cai Lifeng

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference45 articles.

1. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.;Cai;Curr Top Med Chem,2011

2. Mechanisms of viral membrane fusion and its inhibition.;Eckert;Ann Rev Bioch,2001

3. Core structure of gp41 from the HIV envelope glycoprotein.;Chan;Cell,1997

4. HIV-1 inhibition by a peptide.;Jiang;Nature,1993

5. Peptides corresponding to a predictive alpha-helical domain of human-immunodeficiency-virus type-1 gp41 are potent inhibitors of virus-infection.;Wild;Proc Natl Acad Sci U S A,1994

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An N-terminal heptad repeat trimer-based peptide fusion inhibitor exhibits potent anti-H1N1 activity;Bioorganic & Medicinal Chemistry;2024-09

2. Design of Artificial C-Peptides as Potential Anti-HIV-1 Inhibitors Based on 6-HB Formation Mechanism;Protein & Peptide Letters;2024-06

3. Design of MERS-CoV entry inhibitory short peptides based on helix-stabilizing strategies;Bioorganic & Medicinal Chemistry Letters;2024-01

4. Polypeptides inhibit HIV-1 replication by interfering viral Vpu-mediated tetherin degradation;Infectious Medicine;2023-09

5. Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors;European Journal of Medicinal Chemistry;2022-06